Rubing Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rubing Chen has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Qi Zhang
The First Affiliated Hospital of Henan University of Chinese Medicine Department of Andrology, China
2 shared publications - Zulong Wang
The First Affiliated Hospital of Henan University of Chinese Medicine Department of Andrology
2 shared publications Chenming Zhang
College of the Second Clinical Medicine, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan Province, P.R. China
1 shared publication- Guifeng Chang
College of the First Clinical Medicine, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan Province, P.R. China
1 shared publication - Huiyuan Shen
College of the First Clinical Medicine, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan Province, P.R. China
1 shared publication - Jucai Song
Department of Andrology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China
1 shared publication
Latest Publications
- 29 September 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (2) , 3073-3088
Multi-omics genetic study revealing ferroptosis regulator CTSB driving prostate cancer progression by modulating the immune microenvironment
The progression and mechanisms of drug resistance in prostate cancer are highly complex, with the ferroptosis pathway playing a critical role. We utilized multi-omics Mendelian randomization (MR) to assess the genetic causal link between ferroptosis gene/protein expression and prostate cancer, investigating potential mediation by 731 immune cell types. Furthermore, differential expression analysis, immune infiltration analysis, single-cell RNA sequencing, gene set enrichment analysis (GSEA), and drug prediction were integrated for multidimensional validation and mechanistic insight. Our results identified cathepsin B (CTSB) as a key causal risk factor associated with iron death in the development of prostate cancer (odds ratio (OR) > 1, p < 0.01). Colocalization analysis (SNP.PP.H4 > 0.95) ruled out confounding biases. Mediation MR analysis revealed that CTSB partially mediates its carcinogenic effects by regulating various immune cells, such as PD-L1 + monocytes and CD45 + T cells (OR > 1, p < 0.05). Further analysis indicated that CTSB gene/protein expression was highly expressed in normal prostate basal epithelial cells and myeloid cells, while it was downregulated in tumor tissues and neoplastic epithelial cells (p < 0.05). Notably, its expression was positively correlated with the infiltration of multiple immune cell types (cor > 0, p < 0.05). GSEA demonstrated that high CTSB expression was significantly enriched in pro-cancer pathways, including epithelial-mesenchymal transition, angiogenesis, inflammatory response, and apoptosis (normalized enrichment score (NES) > 2, false discovery rate (FDR) < 0.001). Drug prediction analyses suggested that targeting CTSB (e.g., with bortezomib) in combination with immunotherapy may represent a novel therapeutic strategy. This study provides the first evidence of the causal role of iron death-immune interactions in prostate cancer, offering new targets for precision treatment. Graphical Abstract
- 29 September 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (2) , 3073-3088
Multi-omics genetic study revealing ferroptosis regulator CTSB driving prostate cancer progression by modulating the immune microenvironment
The progression and mechanisms of drug resistance in prostate cancer are highly complex, with the ferroptosis pathway playing a critical role. We utilized multi-omics Mendelian randomization (MR) to assess the genetic causal link between ferroptosis gene/protein expression and prostate cancer, investigating potential mediation by 731 immune cell types. Furthermore, differential expression analysis, immune infiltration analysis, single-cell RNA sequencing, gene set enrichment analysis (GSEA), and drug prediction were integrated for multidimensional validation and mechanistic insight. Our results identified cathepsin B (CTSB) as a key causal risk factor associated with iron death in the development of prostate cancer (odds ratio (OR) > 1, p < 0.01). Colocalization analysis (SNP.PP.H4 > 0.95) ruled out confounding biases. Mediation MR analysis revealed that CTSB partially mediates its carcinogenic effects by regulating various immune cells, such as PD-L1 + monocytes and CD45 + T cells (OR > 1, p < 0.05). Further analysis indicated that CTSB gene/protein expression was highly expressed in normal prostate basal epithelial cells and myeloid cells, while it was downregulated in tumor tissues and neoplastic epithelial cells (p < 0.05). Notably, its expression was positively correlated with the infiltration of multiple immune cell types (cor > 0, p < 0.05). GSEA demonstrated that high CTSB expression was significantly enriched in pro-cancer pathways, including epithelial-mesenchymal transition, angiogenesis, inflammatory response, and apoptosis (normalized enrichment score (NES) > 2, false discovery rate (FDR) < 0.001). Drug prediction analyses suggested that targeting CTSB (e.g., with bortezomib) in combination with immunotherapy may represent a novel therapeutic strategy. This study provides the first evidence of the causal role of iron death-immune interactions in prostate cancer, offering new targets for precision treatment. Graphical Abstract
- Open Access
- 28 October 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (43) , e31226
Clinical study of Wuwei Fuzheng Yijing formula in the treatment of sperm DNA damage in male infertility: A study protocol for a randomized controlled trial
Background: The incidence of male infertility is increasing in recent years, and the semen routine examination of some patients is normal, but the semen pathological examination shows that the sperm DNA fragmentation index (DFI) is high, and the patients’ clinical manifestations are infertility or recurrent abortion of their spouses. At present, there is no special treatment for male infertility caused by high DFI, and traditional Chinese medicine compound prescription shows potential value in the treatment of male infertility. Wuwei Fuzheng Yijing formula (WFY) is an effective prescription for the treatment of sperm DNA damage in male infertility, but there is no strict clinical trial to support its application. Therefore, we designed a randomized controlled trial to evaluate the efficacy and safety of WFY in patients with sperm DNA damage in male infertility. Methods: In this randomized controlled study, 100 patients who met the inclusion criteria were randomly divided into WFY group and levocarnitine oral solution group. The treatment period was 12 weeks. The main observation index was sperm DFI, and the secondary observation index was sperm concentration, motility, survival rate, and TCM syndrome score. Safety observation indicators will include electrocardiogram, blood tests (including blood routine tests, liver and renal function), routine urine tests, and routine stool tests. All results were evaluated at the 4th and 8th week of the baseline, and the end of treatment. Discussion: This study will provide a basis for the efficacy and safety of WFY in the treatment of sperm DNA damage in male infertility with spleen and kidney qi deficiency and blood stasis.
- 28 October 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (43) , e31226
Open AccessClinical study of Wuwei Fuzheng Yijing formula in the treatment of sperm DNA damage in male infertility: A study protocol for a randomized controlled trial
Background: The incidence of male infertility is increasing in recent years, and the semen routine examination of some patients is normal, but the semen pathological examination shows that the sperm DNA fragmentation index (DFI) is high, and the patients’ clinical manifestations are infertility or recurrent abortion of their spouses. At present, there is no special treatment for male infertility caused by high DFI, and traditional Chinese medicine compound prescription shows potential value in the treatment of male infertility. Wuwei Fuzheng Yijing formula (WFY) is an effective prescription for the treatment of sperm DNA damage in male infertility, but there is no strict clinical trial to support its application. Therefore, we designed a randomized controlled trial to evaluate the efficacy and safety of WFY in patients with sperm DNA damage in male infertility. Methods: In this randomized controlled study, 100 patients who met the inclusion criteria were randomly divided into WFY group and levocarnitine oral solution group. The treatment period was 12 weeks. The main observation index was sperm DFI, and the secondary observation index was sperm concentration, motility, survival rate, and TCM syndrome score. Safety observation indicators will include electrocardiogram, blood tests (including blood routine tests, liver and renal function), routine urine tests, and routine stool tests. All results were evaluated at the 4th and 8th week of the baseline, and the end of treatment. Discussion: This study will provide a basis for the efficacy and safety of WFY in the treatment of sperm DNA damage in male infertility with spleen and kidney qi deficiency and blood stasis.